Poly Medicure Limited POLYMED NIFTY_SMALLNSEPHARMA
Company Overview
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, such as blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, foley balloon and urine drainage catheters, and urine collection bags with measured volume meters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.
Why Investors Should Care
Net profit has compounded at 22.7% per year over the last five years.
Revenue has grown at a 19.1% CAGR over the past five years.
Maintains a net profit margin of 17.7%.
Carries low leverage with a debt-to-equity ratio of 0.11.
Recent Developments
- Mar 2026 Revenue of ₹1,875.26 Cr (+12.3% YoY); net profit ₹331.29 Cr.
- Trailing 12 Months Year-on-year growth — revenue +12.3%, earnings -2.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.1%, profit CAGR 22.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.15% |
| 1 Year: | 12.30% |
Compounded Profit Growth
| 5 Years: | 22.71% |
| 1 Year: | -2.15% |
Stock Price Performance
| 1 Year: | -24.31% |
| 6 Months: | -5.59% |
| 3 Months: | +12.03% |
| 1 Month: | +10.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.31 · Neutral
P/E of 49.16 is above the sector median of 39.97 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.1% over 5 years.
- Profit CAGR of 22.7% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | POLYMED Poly Medicure Limited NIFTY_SMALLNSEPHARMA | 1,677.00 | 49.16 | ₹16,997.99 Cr | 0.21% | 13.33% | 10.67% | 19.15% | 22.71% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 307.00 Cr | 321.00 Cr | 337.00 Cr | 340.00 Cr | 378.00 Cr | 385.00 Cr | - | - | 440.83 Cr | 403.21 Cr | 443.88 Cr | 493.66 Cr | 534.51 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 148.15 Cr | 127.23 Cr | 135.66 Cr | 312.54 Cr | 178.16 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 292.68 Cr | 275.98 Cr | 308.22 Cr | 181.12 Cr | 356.35 Cr |
| Operating Expenses | 224.00 Cr | 234.00 Cr | 253.00 Cr | 249.00 Cr | 282.00 Cr | 281.00 Cr | - | - | 194.25 Cr | 193.10 Cr | 218.47 Cr | 255.47 Cr | 284.18 Cr |
| Operating Income | 68.00 Cr | 71.00 Cr | 68.00 Cr | 74.00 Cr | 80.00 Cr | 84.00 Cr | - | - | 98.43 Cr | 82.88 Cr | 89.75 Cr | -74.35 Cr | 72.17 Cr |
| EBITDA | 83.00 Cr | 87.00 Cr | 84.00 Cr | 90.00 Cr | 96.00 Cr | 104.00 Cr | - | - | 146.18 Cr | 149.15 Cr | 149.59 Cr | 132.33 Cr | 129.86 Cr |
| Interest Expense | 2.00 Cr | 2.00 Cr | 2.00 Cr | 3.00 Cr | 3.00 Cr | 3.00 Cr | - | - | 2.17 Cr | 2.95 Cr | 2.97 Cr | 5.96 Cr | 6.41 Cr |
| Pretax Income | 75.00 Cr | 83.00 Cr | 81.00 Cr | 88.00 Cr | 92.00 Cr | 98.00 Cr | - | - | 122.85 Cr | 122.95 Cr | 121.69 Cr | 97.61 Cr | 85.22 Cr |
| Tax Provision | 16.50 Cr | 19.92 Cr | 18.63 Cr | 22.88 Cr | 23.92 Cr | 24.50 Cr | - | - | 31.02 Cr | 29.86 Cr | 29.89 Cr | 26.80 Cr | 20.18 Cr |
| Net Income | 59.00 Cr | 63.00 Cr | 62.00 Cr | 65.00 Cr | 68.00 Cr | 74.00 Cr | - | - | 91.83 Cr | 93.08 Cr | 91.83 Cr | 70.93 Cr | 65.04 Cr |
| Diluted EPS | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | - | - | 8.92 | 9.17 | 9.06 | 6.99 | 6.53 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 390.00 Cr | 411.00 Cr | 454.00 Cr | 519.00 Cr | 610.00 Cr | 687.00 Cr | 785.00 Cr | - | 1,108.66 Cr | 1,365.69 Cr | 1,669.83 Cr | 1,875.26 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 509.32 Cr | 604.32 Cr | 555.44 Cr | 596.81 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 599.34 Cr | 761.38 Cr | 1,114.39 Cr | 1,278.45 Cr |
| Operating Expenses | 304.00 Cr | 323.00 Cr | 361.00 Cr | 397.00 Cr | 479.00 Cr | 520.00 Cr | 569.00 Cr | - | 381.49 Cr | 458.72 Cr | 744.18 Cr | 951.65 Cr |
| Operating Income | 67.00 Cr | 67.00 Cr | 69.00 Cr | 93.00 Cr | 94.00 Cr | 125.00 Cr | 168.00 Cr | - | 217.85 Cr | 302.65 Cr | 370.20 Cr | 326.80 Cr |
| EBITDA | 86.00 Cr | 88.00 Cr | 93.00 Cr | 122.00 Cr | 131.00 Cr | 166.00 Cr | 216.00 Cr | - | 303.20 Cr | 418.89 Cr | 547.69 Cr | 561.28 Cr |
| Interest Expense | 10.00 Cr | 10.00 Cr | 8.00 Cr | 12.00 Cr | 14.00 Cr | 20.00 Cr | 11.00 Cr | - | 8.54 Cr | 10.70 Cr | 12.00 Cr | 18.29 Cr |
| Pretax Income | 85.00 Cr | 65.00 Cr | 75.00 Cr | 97.00 Cr | 100.00 Cr | 126.00 Cr | 180.00 Cr | - | 237.49 Cr | 344.27 Cr | 452.52 Cr | 427.47 Cr |
| Tax Provision | 22.95 Cr | 17.55 Cr | 20.25 Cr | 26.19 Cr | 35.00 Cr | 30.24 Cr | 45.00 Cr | - | 58.21 Cr | 86.01 Cr | 113.96 Cr | 96.18 Cr |
| Net Income | 62.00 Cr | 48.00 Cr | 55.00 Cr | 71.00 Cr | 65.00 Cr | 96.00 Cr | 136.00 Cr | - | 179.28 Cr | 258.26 Cr | 338.56 Cr | 331.29 Cr |
| Diluted EPS | 7.07 | 5.47 | 6.25 | 8.00 | 7.41 | 10.86 | 14.17 | 15.27 | 18.67 | 26.90 | 34.11 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 364.00 Cr | 387.00 Cr | 457.00 Cr | 565.00 Cr | 654.00 Cr | 767.00 Cr | 1,224.00 Cr | - | 1,577.21 Cr | 1,858.67 Cr | 3,192.45 Cr | 3,918.57 Cr |
| Current Assets | - | - | - | - | - | - | - | - | 806.69 Cr | 841.60 Cr | 1,917.00 Cr | 1,941.73 Cr |
| Cash & Equivalents | - | - | - | - | - | - | - | - | 7.06 Cr | 12.05 Cr | 8.70 Cr | 51.23 Cr |
| Inventory | - | - | - | - | - | - | - | - | 208.65 Cr | 221.03 Cr | 285.57 Cr | 433.84 Cr |
| Receivables | - | - | - | - | - | - | - | - | 235.43 Cr | 269.94 Cr | 349.73 Cr | 531.17 Cr |
| Total Liabilities | - | - | - | - | - | - | - | - | 335.58 Cr | 388.62 Cr | 426.79 Cr | 769.32 Cr |
| Current Liabilities | - | - | - | - | - | - | - | - | 293.30 Cr | 351.21 Cr | 370.17 Cr | 575.52 Cr |
| Long Term Debt | - | - | - | - | - | - | - | - | 17.50 Cr | 84.05 L | 0 | 52.09 Cr |
| Total Debt | 79.00 Cr | 82.00 Cr | 101.00 Cr | 133.00 Cr | 161.00 Cr | 207.00 Cr | 137.00 Cr | - | 149.02 Cr | 173.90 Cr | 180.25 Cr | 353.58 Cr |
| Total Equity | 196.00 Cr | 229.00 Cr | 271.00 Cr | 338.00 Cr | 381.00 Cr | 435.00 Cr | 966.00 Cr | - | 1,241.63 Cr | 1,470.05 Cr | 2,765.66 Cr | 3,106.17 Cr |
| Shares Outstanding | - | - | - | - | - | - | - | - | 9.59 Cr | 9.60 Cr | 10.13 Cr | 10.14 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 63.00 Cr | 63.00 Cr | 56.00 Cr | 75.00 Cr | 106.00 Cr | 131.00 Cr | 119.00 Cr | - | 191.05 Cr | 266.08 Cr | 233.05 Cr | 246.37 Cr |
| Investing Cash Flow | -59.00 Cr | -31.00 Cr | -56.00 Cr | -88.00 Cr | -101.00 Cr | -109.00 Cr | -436.00 Cr | - | -179.24 Cr | -240.94 Cr | -1,187.18 Cr | -225.38 Cr |
| Financing Cash Flow | -6.00 Cr | -31.00 Cr | -0 | 16.00 Cr | -5.00 Cr | -21.00 Cr | 317.00 Cr | - | -12.51 Cr | -20.15 Cr | 950.51 Cr | 20.15 Cr |
| Capital Expenditure | -50.00 Cr | -32.00 Cr | -56.00 Cr | -82.00 Cr | -75.00 Cr | -106.00 Cr | -95.00 Cr | - | -239.27 Cr | -277.02 Cr | -331.03 Cr | -308.39 Cr |
| Free Cash Flow | 13.00 Cr | 31.00 Cr | -0 | -7.00 Cr | 31.00 Cr | 25.00 Cr | 24.00 Cr | - | -48.22 Cr | -10.93 Cr | -97.98 Cr | -62.02 Cr |
| Net Change in Cash | -2.00 Cr | 1.00 Cr | 0 | 3.00 Cr | 1.00 Cr | 1.00 Cr | 0 | - | -69.49 L | 4.99 Cr | -3.63 Cr | 41.14 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 54.1% | 55.8% | 66.7% | 68.2% |
| Operating Margin % | 17.2% | 16.3% | 15.2% | 17.9% | 15.4% | 18.2% | 21.4% | - | 19.6% | 22.2% | 22.2% | 17.4% |
| Net Margin % | 15.9% | 11.7% | 12.1% | 13.7% | 10.7% | 14.0% | 17.3% | - | 16.2% | 18.9% | 20.3% | 17.7% |
| ROE % | 31.6% | 21.0% | 20.3% | 21.0% | 17.1% | 22.1% | 14.1% | - | 14.4% | 17.6% | 12.2% | 10.7% |
| ROCE % | - | - | - | - | - | - | - | - | 17.0% | 20.1% | 13.1% | 9.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for POLYMED
POLYMED Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBRamdUVWlpX0hWUnJBcU5yR0wxM2haakd0d21mSy1SQVJRZlB1bF9hWWRSMmRWdkVHNlJBd3VfOGo0UjdhQnlxcmx2b2I1U0hmSnFTSDdNUlRhTjZ6aldVX1FFVXhsNkJQM0FCbnlKQVZRZzhZbHR6c0dB?oc=5" target="_blank">POL…
Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQUHRvQnlUZldBRzFoQVI3ellaZ0Y3UF9xdi13RS1Lb2RzSzBvaTJkUUM1LWF2YVJnbmdaU1JrZnVJMHAtUEM1MlhrcUJzdVdFN3RidlRQaXJrazE0SU1KMGcxdkNIaVR3NGJURkMwdHpock13TXgtbVN3UmlVaGtVQmZ2TXg2OTVhek5CS1…
POLYMED: Revenue and profit rose on medical device growth and acquisitions; ₹3.5/share dividend proposed - TradingView
<a href="https://news.google.com/rss/articles/CBMikgJBVV95cUxQYTBhcHpVWktSX2RJVURfdzA0MGF1cGd5RzZuQTQ4R2JOVjRIcDhWNUZhY2g5bDF3UGNNbWY2dGthSUs3cjkxSnBoSkFYdVpMV1B6R1hGNFZqMFJTM0pmTml0LUlZWGNoZlN4eWRqRDY1WTNmZVVTZ1owYS0tdzdpa1FfSFdnTENRUGsyTH…
Poly Medicure Limited's (NSE:POLYMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNV1d5N3J2Z0ZDc1hFbFduNjJMR1dUd0FsbjhFV3NyS3lNb0JsY1RlUWxoalRFdVh0UVdWQ2xqN1V6cEJDVF9NanZOelhqczRfU19lT3lfWlNCdmdoRW45aW84WVB1eC1hTWhqcXVqSklQd3NtMzVPYXdIQWxYTjlJQTl1SHgyejd5LWxLTG…
Poly Medicure Q4 Net Profit Falls 27.8% to ₹66.3 Cr Amid Margin Pressure - Sahi
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQcjY0bllKRU5DZnZGb2l3dEprdHg2dmxDd0V1UElHTUpOX0VEUEhwTF91REU2MklwR1o5ald0MWJIUmtsM1NrMnh3Ql9OLU0xWnM1WWU3X0ZpOEtfb3JLdmR2bU52MFU1YUk4clBRRFZ1WUFseGM2ZlQtTFhRQU01WUsxVi1FUE5mc25SWD…
Poly Medicure Subsidiary Acquires Brazilian Medical Device Company for R$180,000 - scanx.trade
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPUmZjclZRdmdQT21ETWJlY0EycVdWOXRDbTI3QWZEeEFBMGZFbUJvSXVnREdHNjIwLVRLS2duQXJucUNINVRqUVVMRGhETVY2N3hlWnNiMVZIcVF2a0JhUnNNcnRGV1VidF80NnlaTXlZSDljRDUxTWdweGpXZ0dKR1lMQ2dTcGlGdmpBTD…
POLYMED — Frequently Asked Questions
What is the current share price of Poly Medicure Limited (POLYMED)?
As of 2026-07-15 09:52 IST, Poly Medicure Limited (POLYMED) trades at ₹1,677.00 on NSE. Its 52-week range is ₹1,191.10 to ₹2,215.71.
What is the market capitalisation of POLYMED?
Poly Medicure Limited (POLYMED) has a market capitalisation of ₹16,997.99 Cr on NSE.
What is the P/E ratio of POLYMED?
POLYMED trades at a trailing price-to-earnings (P/E) ratio of 49.16. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.39.
Does POLYMED pay a dividend?
Poly Medicure Limited (POLYMED) currently offers a dividend yield of 0.21%.
What is the return on equity (ROE) of POLYMED?
POLYMED has a return on equity (ROE) of 10.67%. Its return on capital employed (ROCE) is 13.33%.
Is POLYMED a good stock to buy?
This page provides a data-driven analysis of Poly Medicure Limited (POLYMED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.